 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
23 News |  |
- | MIV-711 / Medivir
Journal: Synthesis and Biological Evaluation of Novel Piperidine-3-Carboxamide Derivatives as Anti-Osteoporosis Agents Targeting Cathepsin K. (Pubmed Central) - Sep 14, 2024
Molecular docking studies revealed that H-9 formed several hydrogen bonds and hydrophobic interactions with key active-site residues of cathepsin K. In vitro, H-9 demonstrated anti-bone resorption effects that were comparable to those of MIV-711, a cathepsin K inhibitor currently in phase 2a clinical trials for the treatment of bone metabolic disease...Moreover, in vivo experiments showed that H-9 increased the bone mineral density of OVX-induced osteoporosis mice. These results suggest that H-9 is a potent anti-bone resorption agent targeting cathepsin K and warrants further investigation for its potential anti-osteoporosis values.
- || MIV-711 / Medivir
P2a data, Retrospective data, Journal: Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis of a randomised phase 2a clinical trial. (Pubmed Central) - May 20, 2022
These results suggest that H-9 is a potent anti-bone resorption agent targeting cathepsin K and warrants further investigation for its potential anti-osteoporosis values. In a subgroup with predominantly unilateral knee pain, significant reduction in OA pain by MIV-711 100 mg treatment was found, with concurrent beneficial structural effects, highlighting the importance of appropriate pain inclusion criteria in OA trials.
- | MIV-711 / Medivir
Subgruppsanalys av Medivirs fas II-studie med MIV-711 mot artros visar signifikant minskad artrosrelaterad smärta https://t.co/1o2AY9uckq (Twitter) - Feb 28, 2022
- | odanacatib (MK-0822) / Merck (MSD)
Preclinical, Journal: Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro. (Pubmed Central) - May 26, 2021
ODN exerts anti-metastatic action through inhibition of signaling pathway for MMP-9, PI3K and MAPK. This indicates potential therapeutic effects of ODN in the treatment of metastatic breast cancer.
- || MIV-711 / Medivir
Clinical, Journal: Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized, Placebo-Controlled Study. (Pubmed Central) - Aug 19, 2020
P2, P2a
MIV-711 is a novel selective cathepsin K inhibitor with beneficial effects on bone and cartilage in preclinical osteoarthritis models...This treatment may merit further evaluation as a disease-modifying osteoarthritis drug. Medivir.
- | MIV-711 / Medivir
Biomarker, Preclinical, Journal: The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis. (Pubmed Central) - Jul 11, 2019
These beneficial effects of MIV-711 on joint pathology are observed in conjunction with decreases in bone and cartilage biomarkers that have been shown to be clinically attainable in human. The data support the further development of MIV-711 for the treatment of OA.
- | MIV-711 / Medivir
Biomarker, Clinical, Journal: Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. (Pubmed Central) - Jul 11, 2019
Taken together, MIV-711 shows promise for the treatment of bone and cartilage related disorders in humans, such as OA. Trial Registration EudraCT number 2011-003024-12, registered on June 22nd 2011.
- || MIV 710 / Medivir, MIV-711 / Medivir
New P1 trial: A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers (clinicaltrials.gov) - Jul 15, 2018
P1, N=18, Completed, Sponsor: Medivir
- | MIV 710 / Medivir, MIV-711 / Medivir
Trial completion: A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients (clinicaltrials.gov) - Dec 28, 2017
P2, N=50, Completed, Sponsor: Medivir
Trial Registration EudraCT number 2011-003024-12, registered on June 22nd 2011. Active, not recruiting --> Completed
- |||| MIV 710 / Medivir, MIV-711 / Medivir
Trial completion: A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients (clinicaltrials.gov) - Aug 25, 2017
P2a, N=244, Completed, Sponsor: Medivir
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | MIV 710 / Medivir, MIV-711 / Medivir
Enrollment closed, Enrollment change: A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients (clinicaltrials.gov) - Aug 25, 2017
P2, N=50, Active, not recruiting, Sponsor: Medivir
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=80 --> 50
- ||| MIV 710 / Medivir, MIV-711 / Medivir
Enrollment closed: A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients (clinicaltrials.gov) - Dec 23, 2016
P2a, N=244, Active, not recruiting, Sponsor: Medivir
Recruiting --> Active, not recruiting | N=80 --> 50 Recruiting --> Active, not recruiting
- ||||| MIV 710 / Medivir, MIV-711 / Medivir
New P2a trial: A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients (clinicaltrials.gov) - Mar 10, 2016
P2a, N=240, Recruiting, Sponsor: Medivir